Blonanserin N-Oxide Lowers Glucose Levels in Animal Models

Abstract

The N-oxide of anti-psychotic drug Blonanserin (BLNO) was synthesized and tested as a novel molecule to understand its ability in reducing blood glucose levels. Administration of BLNO at 1 mg/kg (mpk, mg of drug per kg of rat body weight) to diabetic Wistar rats (induced by treatment of 40 mg/kg streptozotocin, STZ) showed reduced glucose levels at 100 mg/dL in a 28 day study, compared to the control group (with no drug added only STZ induced) which reached hyperglycemic levels of 500-600 mg/dL. At 5 mpk of BLNO, glucose levels were controlled in a 18 day study and no toxic or adverse indications were observed at the higher 5X dose. Oral glucose tolerance test on Wistar rats confirmed the potential of BLNO to reduce glucose levels at 5 mpk dose, comparable to that of marketed drugs metformin HCl (MHCL) and sitagliptin phosphate monohydrate (SPMH) at 100 mpk dose in 90-120 min after drug administration. A novel molecule Blonanserin-N-oxide is identified as a potential anti-diabetic drug lead for controlling blood glucose levels.